Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Autolus Therapeutics Plc's Business Segments
Autolus Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 26
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 26 | 100% |
Description of Autolus Therapeutics Plc
Autolus Therapeutics Plc is a clinical-stage biopharmaceutical company that specializes in the development and commercialization of next-generation, programmed T cell therapies for the treatment of cancer. The company is based in London, United Kingdom and was founded in 2014.
Autolus Therapeutics focuses on developing therapies that harness the power of a patient's immune system to specifically target cancer cells. They use a proprietary technology called Autologous Redirected Optimized Cell Therapeutics (ARC-T) to engineer T cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs).
The company's lead product candidate is AUTO1, an investigational CAR-T therapy designed to target CD19, a protein expressed on the surface of various B-cell malignancies, including acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). AUTO1 is being evaluated in several clinical trials, including a Phase 1 trial in adult ALL and a Phase 1/2 trial in pediatric ALL.
In addition to AUTO1, Autolus Therapeutics is developing a pipeline of other CAR-T and TCR therapies targeting different cancer antigens, including AUTO3, AUTO4, AUTO6, and AUTO8. These therapies are being developed for the treatment of solid tumors and hematological malignancies.
Autolus Therapeutics' approach to CAR-T and TCR therapies involves refining the manufacturing process to enhance the safety and effectiveness of these therapies. They aim to reduce the risks associated with CAR-T therapies, such as cytokine release syndrome (CRS) and neurotoxicity, by altering certain components of the T cells.
The company has established collaborations with various academic institutions, including UCL (University College London) and The Cell and Gene Therapy Catapult, to advance their research and development efforts. Autolus Therapeutics also has partnerships with commercial organizations, such as Moderna Therapeutics, to leverage their expertise in the field of mRNA-based therapeutics.
Overall, Autolus Therapeutics Plc is a leading player in the field of cell-based immunotherapies, specifically CAR-T and TCR therapies. They are dedicated to developing innovative and potentially curative treatments for patients with cancer, with a focus on improving safety, durability, and efficacy.
Autolus Therapeutics focuses on developing therapies that harness the power of a patient's immune system to specifically target cancer cells. They use a proprietary technology called Autologous Redirected Optimized Cell Therapeutics (ARC-T) to engineer T cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs).
The company's lead product candidate is AUTO1, an investigational CAR-T therapy designed to target CD19, a protein expressed on the surface of various B-cell malignancies, including acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). AUTO1 is being evaluated in several clinical trials, including a Phase 1 trial in adult ALL and a Phase 1/2 trial in pediatric ALL.
In addition to AUTO1, Autolus Therapeutics is developing a pipeline of other CAR-T and TCR therapies targeting different cancer antigens, including AUTO3, AUTO4, AUTO6, and AUTO8. These therapies are being developed for the treatment of solid tumors and hematological malignancies.
Autolus Therapeutics' approach to CAR-T and TCR therapies involves refining the manufacturing process to enhance the safety and effectiveness of these therapies. They aim to reduce the risks associated with CAR-T therapies, such as cytokine release syndrome (CRS) and neurotoxicity, by altering certain components of the T cells.
The company has established collaborations with various academic institutions, including UCL (University College London) and The Cell and Gene Therapy Catapult, to advance their research and development efforts. Autolus Therapeutics also has partnerships with commercial organizations, such as Moderna Therapeutics, to leverage their expertise in the field of mRNA-based therapeutics.
Overall, Autolus Therapeutics Plc is a leading player in the field of cell-based immunotherapies, specifically CAR-T and TCR therapies. They are dedicated to developing innovative and potentially curative treatments for patients with cancer, with a focus on improving safety, durability, and efficacy.
Autolus Therapeutics Plc is a clinical-stage biopharmaceutical company that specializes in the development of innovative engineered T-cell therapies designed to address various types of cancer. The company is dedicated to transforming cancer treatment and enhancing patient outcomes through its advanced therapeutic approaches.
Segments
1. Product Development: This segment focuses on creating novel therapies utilizing proprietary technology platforms. Autolus Therapeutics product development efforts are multi-faceted, encompassing therapies designed for different cancers which leverage diverse engineering methodologies.
2. Clinical Trials: Autolus Therapeutics is actively involved in conducting clinical trials to assess the safety and efficacy of its investigational therapies. The company collaborates with prominent academic institutions and clinical research organizations to implement these trials, assessing the effects of therapies on patients suffering from different cancer types.
3. Manufacturing: The manufacturing segment is crucial for Autolus Therapeutics, as it has established scalable production processes for its T-cell therapies. This segment entails the development and operation of manufacturing facilities equipped with cutting-edge technology and skilled personnel, ensuring that therapies can be produced efficiently and made available for broader patient populations once they receive regulatory approval.
Products
1. AUTO1: AUTO1 represents Autolus Therapeutics lead product candidate, focusing on a CD19-targeted CAR T-cell therapy aimed at treating adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). It has been specifically engineered to enhance safety profiles and minimize toxicity when compared to existing CAR T-cell therapies, addressing a significant need for effective treatment options.
2. AUTO3: This investigational product is a dual-targeted CAR T-cell therapy that targets both CD19 and CD22. It is under evaluation for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and pediatric ALL. Striving to address the risk of antigen escape in cancer cells, AUTO3s design aims to simultaneously target the two antigens, enhancing therapeutic efficacy.
3. Preclinical Pipeline: Beyond its lead candidates, Autolus Therapeutics maintains a dynamic preclinical pipeline, featuring a variety of potential product candidates. These candidates include innovative therapies with unique target antigens and specialized modifications, all tailored to improve safety, efficacy, and manufacturing efficiency.
Services
1. Patient Enrollment and Support: The company is dedicated to providing comprehensive support to patients participating in its clinical trials. This includes facilitating access to treatments, offering financial assistance programs, and developing personalized care plans to help manage any side effects, thereby maximizing the benefits of treatment.
2. Collaboration and Partnerships: Autolus Therapeutics actively seeks to foster collaborations with academic institutions, research organizations, and other pharmaceutical entities. By pooling resources, expertise, and knowledge, these partnerships are established to accelerate the development and eventual commercialization of new cancer therapies.
3. Education and Advocacy: The company is committed to enhancing the understanding of T-cell therapies among healthcare professionals, patients, and their families. Through participation in scientific conferences and patient advocacy forums, Autolus Therapeutics aims to disseminate knowledge regarding the benefits and potential risks of engineered T-cell therapies, promoting better awareness within the community.
Summary
In summary, Autolus Therapeutics Plc is at the forefront of developing engineered T-cell therapies aimed at revolutionizing cancer treatment. Its efforts span across several key segments, including product development, clinical trials, and manufacturing, as well as offering support services like patient enrollment and advocacy. The companys innovative product candidates, such as AUTO1 and AUTO3, along with a robust preclinical pipeline, highlight its commitment to addressing unmet medical needs in cancer care. Through strategic collaborations and educational initiatives, Autolus Therapeutics is positioned to make significant contributions to the field of oncology and enhance the lives of cancer patients.
Segments
1. Product Development: This segment focuses on creating novel therapies utilizing proprietary technology platforms. Autolus Therapeutics product development efforts are multi-faceted, encompassing therapies designed for different cancers which leverage diverse engineering methodologies.
2. Clinical Trials: Autolus Therapeutics is actively involved in conducting clinical trials to assess the safety and efficacy of its investigational therapies. The company collaborates with prominent academic institutions and clinical research organizations to implement these trials, assessing the effects of therapies on patients suffering from different cancer types.
3. Manufacturing: The manufacturing segment is crucial for Autolus Therapeutics, as it has established scalable production processes for its T-cell therapies. This segment entails the development and operation of manufacturing facilities equipped with cutting-edge technology and skilled personnel, ensuring that therapies can be produced efficiently and made available for broader patient populations once they receive regulatory approval.
Products
1. AUTO1: AUTO1 represents Autolus Therapeutics lead product candidate, focusing on a CD19-targeted CAR T-cell therapy aimed at treating adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). It has been specifically engineered to enhance safety profiles and minimize toxicity when compared to existing CAR T-cell therapies, addressing a significant need for effective treatment options.
2. AUTO3: This investigational product is a dual-targeted CAR T-cell therapy that targets both CD19 and CD22. It is under evaluation for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and pediatric ALL. Striving to address the risk of antigen escape in cancer cells, AUTO3s design aims to simultaneously target the two antigens, enhancing therapeutic efficacy.
3. Preclinical Pipeline: Beyond its lead candidates, Autolus Therapeutics maintains a dynamic preclinical pipeline, featuring a variety of potential product candidates. These candidates include innovative therapies with unique target antigens and specialized modifications, all tailored to improve safety, efficacy, and manufacturing efficiency.
Services
1. Patient Enrollment and Support: The company is dedicated to providing comprehensive support to patients participating in its clinical trials. This includes facilitating access to treatments, offering financial assistance programs, and developing personalized care plans to help manage any side effects, thereby maximizing the benefits of treatment.
2. Collaboration and Partnerships: Autolus Therapeutics actively seeks to foster collaborations with academic institutions, research organizations, and other pharmaceutical entities. By pooling resources, expertise, and knowledge, these partnerships are established to accelerate the development and eventual commercialization of new cancer therapies.
3. Education and Advocacy: The company is committed to enhancing the understanding of T-cell therapies among healthcare professionals, patients, and their families. Through participation in scientific conferences and patient advocacy forums, Autolus Therapeutics aims to disseminate knowledge regarding the benefits and potential risks of engineered T-cell therapies, promoting better awareness within the community.
Summary
In summary, Autolus Therapeutics Plc is at the forefront of developing engineered T-cell therapies aimed at revolutionizing cancer treatment. Its efforts span across several key segments, including product development, clinical trials, and manufacturing, as well as offering support services like patient enrollment and advocacy. The companys innovative product candidates, such as AUTO1 and AUTO3, along with a robust preclinical pipeline, highlight its commitment to addressing unmet medical needs in cancer care. Through strategic collaborations and educational initiatives, Autolus Therapeutics is positioned to make significant contributions to the field of oncology and enhance the lives of cancer patients.